KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EBT (2020 - 2025)

Ginkgo Bioworks Holdings filings provide 6 years of EBT readings, the most recent being -$81.4 million for Q4 2025.

  • On a quarterly basis, EBT rose 24.54% to -$81.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$313.6 million, a 42.72% increase, with the full-year FY2025 number at -$313.6 million, up 42.72% from a year prior.
  • EBT hit -$81.4 million in Q4 2025 for Ginkgo Bioworks Holdings, down from -$80.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$54.9 million in Q2 2021 to a low of -$1.6 billion in Q4 2021.
  • Median EBT over the past 5 years was -$169.6 million (2023), compared with a mean of -$285.7 million.
  • Biggest five-year swings in EBT: tumbled 3361.18% in 2021 and later skyrocketed 88.3% in 2022.
  • Ginkgo Bioworks Holdings' EBT stood at -$1.6 billion in 2021, then skyrocketed by 88.3% to -$187.8 million in 2022, then decreased by 12.8% to -$211.9 million in 2023, then surged by 49.1% to -$107.9 million in 2024, then grew by 24.54% to -$81.4 million in 2025.
  • The last three reported values for EBT were -$81.4 million (Q4 2025), -$80.8 million (Q3 2025), and -$60.6 million (Q2 2025) per Business Quant data.